The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Tumor angiogenesis: past, present and the near future
Abstract
The concept of treating solid tumors by inhibiting tumor angiogenesis was first articulated almost 30 years ago. For the next 10 years it attracted little scientific interest. This situation changed, relatively slowly, over the succeeding decade with the discovery of the first pro-angiogenic molecules such as basic fibroblast growth factor and vascular endothelial growth factor (VEGF), and the development of methods of successfully growing vascular endothelial cells in culture as well as in vivo assays of angiogenesis. However, the 1990s have witnessed a striking change in both attitude and interest in tumor angiogenesis and anti-angiogenic drug development, to the point where a remarkably diverse group of over 24 such drugs is currently undergoing evaluation in phase I, II or III clinical trials. In this review I will discuss the many reasons for this. These features, together with other recent discoveries have created intense interest in initiating and expanding anti-angiogenic drug discovery programs in both academia and industry, and the testing of such newly developed drugs, either alone, or in various combinations with conventional cytotoxic therapeutics. However, significant problems remain in the clinical application of angiogenesis inhibitors such as the need for surrogate markers to monitor the effects of such drugs when they do not cause tumor regressions, and the design of clinical trials. Also of concern is that the expected need to use anti-angiogenic drugs chronically will lead to delayed toxic side effects in humans, which do not appear in rodents, especially in short-term studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81813-9 · Cited by 2,847
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & Harmon, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j · Cited by 2,132
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81812-7 · Cited by 1,989
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Isolation of a tumor factor responsible for angiogenesis
Folkman, J., Merler, E., Abernathy, C., & Williams, G. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.133.2.275 · Cited by 1,663
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., & Keshet, E. (1995) · Nature Medicine · doi:10.1038/nm1095-1024 · Cited by 1,604
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Carmeliet, P., Lampugnani, M.-G., Moons, L., Breviario, F., Compernolle, V., Bono, F., Balconi, G., Spagnuolo, R., Oosthuyse, B., Dewerchin, M., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81010-7 · Cited by 1,283
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Signaling Vascular Morphogenesis and Maintenance
Hanahan, D. (1997) · Science · doi:10.1126/science.277.5322.48 · Cited by 1,190
Anti-Angiogenesis: New Concept for Therapy of Solid Tumors
Folkman, J. (1972) · Annals of Surgery · doi:10.1097/00000658-197203000-00014 · Cited by 1,171
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationFong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,109
Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Folkman, J., & Haudenschild, C. (1980) · Nature · doi:10.1038/288551a0 · Cited by 1,037
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Isner, J. M., Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., & Symes, J. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03361-2 · Cited by 989
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Gerber, H.-P., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.13313 · Cited by 981
Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor
Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J., & Klagsbrun, M. (1984) · Science · doi:10.1126/science.6199844 · Cited by 933
VEGF is required for growth and survival in neonatal mice
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 915
Intratumor microvessel density as a prognostic factor in cancer.
Weidner, N. (1995) · PubMed Central · Cited by 866
Vascular permeability factor (VPF, VEGF) in tumor biology
Senger, D. R., Van De Water, L., Brown, L. F., Nagy, J. A., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R. W., Dvorak, A. M., & Dvorak, H. F. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665960 · Cited by 840
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Self-citationChang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Passaniti, A., Taylor, R. M., Пили, Р., Guo, Y., Long, P., Haney, J. A., Pauly, R. R., Grant, D. S., & Martin, G. R. (1992) · PubMed · Cited by 806
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Self-citationMatrix Metalloproteinases Regulate Neovascularization by Acting as Pericellular Fibrinolysins
Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R., & Weiss, S. J. (1998) · Cell · doi:10.1016/s0092-8674(00)81768-7 · Cited by 712
Moulton, K. S., Heller, E., Konerding, M. A., Flynn, E., Palinski, W., & Folkman, J. (1999) · Circulation · doi:10.1161/01.cir.99.13.1726 · Cited by 688
Combined effects of angiostatin and ionizing radiation in antitumour therapy
Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M.-J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., et al. (1998) · Nature · doi:10.1038/28412 · Cited by 668
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., & Taraboletti, G. (1996) · PubMed · Cited by 643
Nör, J. E., Christensen, J., Mooney, D. J., & Polverini, P. J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65284-4 · Cited by 641
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Ikeda, E., Achen, M. G., Breier, G., & Risau, W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19761 · Cited by 594
Tolsma, S., Volpert, O., Good, D., Frazier, W., Polverini, P., & Bouck, N. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.2.497 · Cited by 573
Delivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and Strategies
Jain, R. K. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.570 · Cited by 557
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.
Pérez‐Atayde, A. R., Sallan, S. E., Tedrow, U. B., Connors, S. L., Allred, E. N., & Folkman, J. (1997) · Europe PMC (PubMed Central) · Cited by 553
Vascular Endothelial Growth Factor: Molecular and Biological Aspects
Ferrara, N. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_1 · Cited by 533
Schumacher, B., Pecher, P., von Specht, B. U., & Stegmann, T. (1998) · Circulation · doi:10.1161/01.cir.97.7.645 · Cited by 531
Proceedings: Tumor angiogenesis factor.
Folkman, J. (1974) · PubMed · Cited by 516
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60862-3 · Cited by 510
VEGFs, receptors and angiogenesis
Veikkola, T., & Alitalo, K. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0091 · Cited by 508
Benjamin, L. E., & Keshet, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8761 · Cited by 506
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature
Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., & Thorpe, P. E. (1997) · Science · doi:10.1126/science.275.5299.547 · Cited by 477
Algire, G. H., Chalkley, H. W., Legallais, F. Y., & Park, H. D. (1945) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/6.1.73 · Cited by 472
Parish, C. R., Freeman, C. G., Brown, K. J., Francis, D. J., & Cowden, W. B. (1999) · PubMed · Cited by 445
Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy
Barlow, C. F., Priebe, C. J., Mulliken, J. B., Barnes, P. D., Mac Donald, D., Folkman, J., & Ezekowitz, R. A. B. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70034-4 · Cited by 441
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Self-citationSingh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 440
Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin
O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., & Folkman, J. (1999) · Science · doi:10.1126/science.285.5435.1926 · Cited by 432
Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice
Killion, J. J., Radinsky, R., & Fidler, I. J. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006140513233 · Cited by 430
Vázquez, F., Hastings, G., Ortega, M.-A., Lane, T. F., Oikemus, S., Lombardo, M., & Iruela-Arispe, M. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23349 · Cited by 426
Dumont, D., Yamaguchi, T. P., Conlon, R. A., Rossant, J., & Breitman, M. L. (1992) · PubMed · Cited by 410
Quantitative angiogenesis assays: Progress and problems
Jain, R. K., Schlenger, K., Hockel, M., & Yuan, F. (1997) · Nature Medicine · doi:10.1038/nm1197-1203 · Cited by 385
Jain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., & Keshet, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10820 · Cited by 374
Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
Denekamp, J. (1993) · The British Journal of Radiology · doi:10.1259/0007-1285-66-783-181 · Cited by 358
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., & Hanahan, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.2002 · Cited by 344
The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
Clapp, C., MARTIAL, J. A., Guzman, R. C., Rentier-Delure, F., & Weiner, R. I. (1993) · Endocrinology · doi:10.1210/en.133.3.1292 · Cited by 340
Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P. L., Gazdar, A. F., King, S. W., Letarte, M., Vitetta, E. S., & Thorpe, P. E. (1995) · PubMed · Cited by 334
Borgström, P., Hillan, K. J., Sriramarao, P., & Ferrara, N. (1996) · PubMed · Cited by 331
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., & Marmé, D. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25915 · Cited by 329
Wizigmann-Voos, S., Breier, G., Risau, W., & Plate, K. H. (1995) · PubMed · Cited by 326
The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis
Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., & Zardi, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590507 · Cited by 316
Chishima, T., Miyagi, Y., Wang, X., Yamaoka, H., Shimada, H., Moossa, A. R., & Hoffman, R. M. (1997) · PubMed · Cited by 310
Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth
Pike, S. E., Yao, L., Jones, K. D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Teruya-Feldstein, J., Wirth, P., Gupta, G., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2349 · Cited by 310
Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny‐Baron, G., & Marmé, D. (1996) · PubMed · Cited by 308
Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., & Böhlen, P. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006094117427 · Cited by 307
Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A., Sullivan, S., Rolland, A., Ralston, R., et al. (1999) · Nature Biotechnology · doi:10.1038/7895 · Cited by 299
Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth
Cao, Y., Chen, A., An, S. S. A., Ji, R.-W., Davidson, D., Cao, Y., & Llinás, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22924 · Cited by 293
Cell adhesion and angiogenesis.
Bischoff, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119168 · Cited by 291
Antiangiogenic Activity of Restin, NC10 Domain of Human Collagen XV: Comparison to Endostatin
Ramchandran, R., Dhanabal, M., Volk, R., Waterman, M. J. F., Segal, M., Lu, H., Knebelmann, B., & Sukhatme, V. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0248 · Cited by 290
(1968) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/41.1.111 · Cited by 283
Neri, D., Carnemolla, B., Nissim, A., Leprini, A., Querzè, G., Balza, E., Pini, A., Tarli, L., Halin, C., Neri, P., et al. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1271 · Cited by 282
Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein
Jackson, D., Volpert, O., Bouck, N., & Linzer, D. (1994) · Science · doi:10.1126/science.7527157 · Cited by 247
Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A., Phil, D., Ebb, D., Smith, P. S., & Folkman, J. (1999) · Pediatrics · doi:10.1542/peds.103.6.1145 · Cited by 245
Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
Rak, J. W., St Croix, B. D., & Kerbel, R. S. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199502000-00001 · Cited by 243
Self-citationAngiogenesis Inhibitors Generated by Tumors
Folkman, J. (1995) · Molecular Medicine · doi:10.1007/bf03401559 · Cited by 215
Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results
Sellke, F. W., Laham, R. J., Edelman, E. R., Pearlman, J. D., & Simons, M. (1998) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(98)00340-3 · Cited by 215
Joseph, I. B. J., Nelson, J. B., Denmeade, S. R., & Isaacs, J. T. (1997) · PubMed · Cited by 211
Pham, C. D., Roberts, T. P. L., Van Bruggen, N., Melnyk, O., Mann, J., Ferrara, N., Cohen, R. L., & Brasch, R. C. (1998) · Cancer Investigation · doi:10.3109/07357909809039771 · Cited by 208
A High-Affinity Human Antibody That Targets Tumoral Blood Vessels
Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D., & Zardi, L. (1999) · Blood · doi:10.1182/blood.v94.1.192.413k22_192_198 · Cited by 206
The Angiopoietins: Yin and Yang in Angiogenesis
Davis, S., & Yancopoulos, G. D. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_9 · Cited by 205
Gelmon, K. A., Eisenhauer, E. A., Harris, A. L., Ratain, M. J., & Workman, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1281 · Cited by 204
Expression of organ-specific antigens on capillary endothelial cells
Auerbach, R., Alby, L., Morrissey, L. W., Tu, M., & Joseph, J. (1985) · Microvascular Research · doi:10.1016/0026-2862(85)90028-7 · Cited by 200
Microvascular Injury in Pathogenesis of Interferon-Induced Necrosis of Subcutaneous Tumors in Mice
Dvorak, H. F., & Gresser, I. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.7.497 · Cited by 192
Conventional cancer therapy: promise broken or promise delayed?
Tannock, I. F. (1998) · The Lancet · doi:10.1016/s0140-6736(98)90327-0 · Cited by 191
Cell adhesion and angiogenesis
Strömblad, S., & Cheresh, D. A. (1996) · Trends in Cell Biology · doi:10.1016/0962-8924(96)84942-7 · Cited by 175
Signaling angiogenesis and lymphangiogenesis
Korpelainen, E. I., & Alitalo, K. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80137-3 · Cited by 174
Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L., & Jonathan Zwi, L. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90391-p · Cited by 172
Seo, M. S., Kwak, N., Ozaki, H., Yamada, H., Okamoto, N., Yamada, E., Fabbro, D., Hofmann, F., Wood, J. M., & Campochiaro, P. A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65430-2 · Cited by 169
Establishing a Link between Oncogenes and Tumor Angiogenesis
Kerbel, R. S., Viloria‐Petit, A., Okada, F., & Rak, J. W. (1998) · Molecular Medicine · doi:10.1007/bf03401737 · Cited by 168
Self-citationVEGF/VPF: The angiogenesis factor found?
Klagsbrun, M., & Soker, S. (1993) · Current Biology · doi:10.1016/0960-9822(93)90073-w · Cited by 163
ZHAI, Y., NI, J., JIANG, G., LU, J., XING, L., LINCOLN, C., CARTER, K. C., JANAT, F., KOZAK, D., XU, S., et al. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.181 · Cited by 158
Vacca, A., Ribatti, D., Ruco, L., Giacchetta, F., Nico, B., Quondamatteo, F., Ria, R., Iurlaro, M., & Dammacco, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690154 · Cited by 148
Iyer, S., Chaplin, D. J., Rosenthal, D. S., et al. (1998) · PubMed · Cited by 147
Rajkumar, S. V., Fonseca, R., Witzig, T. E., Gertz, M. A., & Greipp, P. (1999) · Leukemia · doi:10.1038/sj.leu.2401336 · Cited by 147
Gupta, S. K., Hassel, T., & Singh, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7799 · Cited by 141
Ramakrishnan, S., Olson, T. A., Bautch, V. L., & Mohanraj, D. (1996) · PubMed · Cited by 139
Complete Remission of Metastatic Cervical Cancer with the Angiogenesis Inhibitor TNP-470
Kudelka, A. P., Verschraegen, C. F., & Loyer, E. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804023381412 · Cited by 126
Antiangiogenic Agents in Cancer Therapy
Teicher, B. A. (1999) · Humana Press eBooks · doi:10.1007/978-1-59259-453-5 · Cited by 124
Frouge, C., RE, E.-M. G., Contesso, G., Paola, R. D., & Bl�ry, M. (1994) · Investigative Radiology · doi:10.1097/00004424-199412000-00006 · Cited by 122
Approaches to studying cell adhesion molecules in angiogenesis
Bischoff, J. E. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)88949-7 · Cited by 120
Re: Gene Therapy Strategies for Tumor Antiangiogenesis
Stenram, U. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.13.1017-a · Cited by 118
Chemotherapy targeted to tumor vasculature
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Current Opinion in Oncology · doi:10.1097/00001622-199811000-00014 · Cited by 108
Zhu, Z., Rockwell, P., Lu, D., Kotanides, H., Pytowski, B., Hicklin, D. J., Böhlen, P., & Witte, L. (1998) · PubMed · Cited by 106
O'Leary, J. J., Shapiro, R. L., Ren, C. J., Chuang, N., Cohen, H. W., & Potmĕsil, M. (1999) · PubMed · Cited by 96
Burt, H. M., Jackson, J. K., Bains, S. K., Liggins, R., Oktaba, A. M., Arsenault, A. L., & Hunter, W. L. (1995) · Cancer Letters · doi:10.1016/0304-3835(94)03614-o · Cited by 93
Tsurumi, Y., Kearney, M., Chen, D., Silver, M., Takeshita, S., Yang, J., Symes, J. F., & Isner, J. M. (1997) · PubMed · Cited by 92
Ji, W.-R., Barrientos, L. G., Llinás, M., Gray, H., Villarreal, X. C., DeFord, M. E., Castellino, F., Kramer, R. A., & Trail, P. A. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8825 · Cited by 88
The growth of the blood supply to melanoma transplants in the hamster cheek pouch
Warren, B. A., & Shubik, P. (1966) · Transplantation · doi:10.1097/00007890-196609000-00032 · Cited by 86
Receptor tyrosine kinases as targets for inhibition of angiogenesis
Shawver, L. K., Lipson, K. E., Fong, T. A. T., McMahon, G., Plowman, G. D., & Strawn, L. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(96)10053-2 · Cited by 83
Inhibitors of Angiogenesis Enter Phase III Testing
Nelson, N. J. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.13.960a · Cited by 80
Cancer and Atherosclerosis: The Broad Mandate of Angiogenesis
Isner, J. M. (1999) · Circulation · doi:10.1161/01.cir.99.13.1653 · Cited by 79
DNA alterations in cancer : genetic and epigenetic changes
Ehrlich, M. (2000) · Medical Entomology and Zoology · Cited by 76
Clinical trials of antiangiogenic agents
Twardowski, P. W., & Gradishar, W. J. (1997) · Current Opinion in Oncology · doi:10.1097/00001622-199711000-00015 · Cited by 62
Teicher, B. A., Dupuis, N. P., Robinson, M., Emi, Y., & Goff, D. A. (1995) · PubMed · Cited by 61
Folkman, J. (1999) · Nature Biotechnology · doi:10.1038/11676 · Cited by 56
Rak, J. W., Hegmann, E. J., Lü, C., & Kerbel, R. S. (1994) · Journal of Cellular Physiology · doi:10.1002/jcp.1041590208 · Cited by 54
Self-citationMeier, P., & Evan, G. I. (1998) · Cell · doi:10.1016/s0092-8674(00)81760-2 · Cited by 53
Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye, S. B. (1998) · PubMed · Cited by 52
Clinical trials of antiangiogenic agents
Hawkins, M. (1995) · Current Opinion in Oncology · doi:10.1097/00001622-199501000-00014 · Cited by 45
Vascular Endothelial Growth Factor Molecular and Biological Aspects
Ferrara, N., & Gerber, H. P. (1999) · Advances in organ biology · doi:10.1016/s1569-2590(08)60162-7 · Cited by 44
Matsuzaki, S., Canis, M., Darcha, C., Dechelotte, P., Pouly, J. L., & Bruhat, M. A. (1998) · Gynecologic and Obstetric Investigation · doi:10.1159/000010013 · Cited by 43
Interleukin 12: Newest Member of the Antiangiogenesis Club
Kerbel, R. S., & Hawley, R. G. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.557 · Cited by 38
Self-citationAngiogenesis Research Is on Fast Forward
Nelson, N. J. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.10.820 · Cited by 23
Schlaeppi, J.-M., Siemeister, G., Weindel, K., Schnell, C., & Wood, J. M. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050283 · Cited by 17
Gene Therapy Strategies for Tumor Antiangiogenesis
Kong, H.-L., & Crystal, R. G. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.4.261-a · Cited by 3
Cited by
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
“These include metabolic stress (for example, low p O 2 , low pH or hypoglycaemia), mechanical stress (for example, pressure generated by proliferating cells), immune/inflammatory response (for example, immune/inflammatory cells that have infiltrated the tissue), and genetic mutations (for example, activation of oncoge…”
BackgroundPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Metadata
- Authors
- Kerbel, R. S.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03
- Volume
- 21
- Issue
- 3
- Pages
- 505-515
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2150048971
- Cited by
- 976
- References
- 150
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.